Clinical Trials on Bone Marrow Neoplasms

Total 128755 results

Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE)

Primary Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis | Post-Polycythemia Vera-Myelofibrosis

Belgium, Italy, Spain, Bulgaria, Turkey, Greece, Russian Federation, Austria, Canada, Japan, Germany
John Mascarenhas
National Cancer Institute (NCI); Novartis; Incyte Corporation; Myeloproliferative...

Terminated

Ruxolitinib Prior to Transplant in Patients With Myelofibrosis

Primary Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Canada, United Kingdom
John Mascarenhas

Terminated

Anti-TGF-beta Therapy in Patients With Myelofibrosis

Primary Myelofibrosis | Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Post-essential Thrombocythemia Related Myelofibrosis

United States
Sanofi

Completed

Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Myelofibrosis

Japan
University Hospital, Bordeaux

Recruiting

Role of Monocytes Sub-populations in Thrombosis Associated With Myeloproliferative Neoplasms (MonSThr) (MonSThr)

Myeloproliferative Neoplasm

France
University Hospital, Bordeaux

Completed

Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms (MPN-BIOCLOT)

Myeloproliferative Neoplasm

France
Incyte Corporation

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

MPN (Myeloproliferative Neoplasms)

United States, France, United Kingdom, Spain, Canada, Japan, Germany, Switzerland, Belgium, Austria, Italy
Memorial Sloan Kettering Cancer Center

Completed

Geriatric Communication Skills Training Program for Oncology Clinicians

Lymphoma | Bone Marrow Transplant | GI Cancer | GU Cancer

United States
Genzyme, a Sanofi Company

Completed

Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation

Bone Marrow / Autologous Transplants

France
M.D. Anderson Cancer Center
Cephalon

Completed

CEP-701 for PH-negative Myelofibrosis

Leukemia | Myelofibrosis

United States
Fondazione per la Ricerca Ospedale Maggiore
European Leukemia Net

Recruiting

Myeloproliferative Neoplasms (MPN) and COVID-19 (MPN-COVID)

COVID | Myeloproliferative Neoplasm

Spain, Italy, France, United States, Bulgaria, Croatia, Germany, Poland, United Kingdom
Incyte Corporation

Active, not recruiting

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, Belgium, France, Israel, China, Japan, Italy, Germany, Taiwan, Poland, Austria, Finland, Hungary, Norway, Romania, Turkey
Sierra Oncology, Inc.

Completed

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis (Simplify 1)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, France, Germany, Spain, Israel, Bulgaria, Romania, Japan, Taiwan, Korea, Republic of, Australia, Belgium, Canada, Netherlands, Singapore, Poland, Hungary, Denmark, Sweden, United Kingdom, Czechia, Austria
Hoffmann-La Roche

Completed

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera | Post-Essential Thrombocythemia Myelofibrosis

United States, Netherlands, Italy, United Kingdom, Canada, France, Germany, Israel
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Australia, Belgium, Czechia, France, Germany, Hungary, Italy, Netherlands, New Zealand, Russian Federation, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential Thrombocythemia

United States
Ronald Hoffman
Novartis

Unknown

LBH589 (Panobinostat) for the Treatment of Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Post-Essential Thrombocythemia Related Myelofibrosis

United States
Pei-Yuan Lee, MD
Aeon Biotechnology Corporation

Unknown

Autologous Bone Marrow Concentration for Femoral Shaft Fracture Union

Femoral Shaft Fracture | Bone Marrow

Taiwan
M.D. Anderson Cancer Center

Completed

Pegasys® in Patients With Myeloproliferative Diseases

Myeloproliferative Disorders

United States
Incyte Corporation
Novartis

Completed

Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

Myelofibrosis

France, United Kingdom, China, United States, Netherlands, Germany, Italy, Austria
Mayo Clinic
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders

Leukemia | Chronic Myeloproliferative Disorders

United States
Hangzhou GluBio Pharmaceutical Co., Ltd.

Recruiting

A Study of GLB-001 in Patients With Myeloid Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myeloid Malignancy

China
Bristol-Myers Squibb

Recruiting

A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Real World Evidence of Fedratinib Effectiveness in MF (REALFed)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Italy
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Terminated

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Thailand, Malaysia, Korea, Republic of, Italy, United Kingdom, Poland, Germany, Turkey
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Completed

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Canada
Novartis Pharmaceuticals

Completed

A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis (JAKoMo)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Germany
Novartis Pharmaceuticals

Completed

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

Idiopathic Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia-Vera Myelofibrosis

United Kingdom, Ireland, Germany, Italy, France
National Institutes of Health Clinical Center (CC)

Completed

Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders

Polycythemia Vera | Chronic Myeloproliferative Disorders | Essential Thrombocytosis | Idiopathic Myelofibrosis | Neutrophils

United States
AstraZeneca
University of Texas; Gustave Roussy, Cancer Campus, Grand Paris; New York City...

Completed

Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

Primary Myelofibrosis (PMF) | Post-Polycythaemia Vera | Essential Thrombocythaemia Myelofibrosis

United States, France
Nantes University Hospital

Terminated

Bone Demineralization Lesions in the Injured Marrow: Efficacy and Tolerability of Administration Early and Repeated the Zoledronic Acid. Comparative Study, Prospective, Double-blind Controlled (DBMZol) (DBMZol)

Bone Demineralization Lesions in the Injured Marrow

France
David Rizzieri, MD

Completed

Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes

Sickle Cell Anemia | Pure Red Cell Aplasia | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Severe Aplastic Anemia

United States
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag

Anemia, Diamond-Blackfan

United States
Centre Leon Berard

Withdrawn

A Study to Assess a Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Allografts (EVAADE)

Myelodysplastic Syndromes | Severe Combined Immunodeficiency | Acute Leukemia | Haematological Malignancy | Hemoglobinopathy in Children | Bone Marrow Aplasia

France
National Heart, Lung, and Blood Institute (NHLBI)

Completed

A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia

Neutropenia | Pancytopenia | Aplastic Anemia | Severe Aplastic Anemia

United States
Centre Leon Berard

Recruiting

Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation (EVAADE)

Myelodysplastic Syndromes | Severe Combined Immunodeficiency | Acute Leukemia | Haematological Malignancy | Hemoglobinopathy in Children | Bone Marrow Aplasia

France
St. Jude Children's Research Hospital
St. Baldrick's Foundation

Completed

Cognitive, Academic and Psychosocial Functioning in Long-Term Survivors of Pediatric Stem Cell Transplantation

Stem Cell Transplant During Childhood | Allogeneic Bone Marrow Transplant During Childhood

United States
Novartis

Completed

Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma

Treatment of Bone Metastases

China
Washington University School of Medicine

Recruiting

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Hemoglobinopathies | Bone Marrow Failure Syndromes | Metabolic Disorders | Non-malignant Disorders | Severe Sickle Cell Disease | Immunologic Disorders

United States
Children's Hospital Medical Center, Cincinnati
FDA Office of Orphan Products Development

Completed

Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia

Fanconi Anemia

United States
Northwell Health

Terminated

Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia (ACE-011-DBA)

Diamond Blackfan Anemia

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia

Diamond Blackfan Anemia

United States
Memorial Sloan Kettering Cancer Center
Boston Children's Hospital; Fred Hutchinson Cancer Center; Children's Hospital... and other collaborators

Completed

Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

Leukemia | Myelodysplastic Syndrome | Aplastic Anemia

United States
Institute of Hematology & Blood Diseases Hospital

Unknown

Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)

Urination Disorders | Thrombosis | Proteinuria | Anemia, Hemolytic | Hemoglobinuria, Paroxysmal | Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria | Bone Marrow Failure | Aplastic Anemia,

China
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia (HAPLO-EMPTY)

Refractory Idiopathic Aplastic Anemia | Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation
Kirsten Grønbæk
Zealand University Hospital; University of Copenhagen; Herlev Hospital; Steno Diabetes... and other collaborators

Recruiting

Repurposing Metformin as a Leukemia-preventive Drug in CCUS and LR-MDS

Preleukemia | Cytopenia | Myelodysplastic Neoplasm | Preleukemic Anemia

Denmark
Federal Scientific Clinical Centre of Pediatric...

Unknown

L-leucine in Diamond Blackfan Anemia Patients

Diamond Blackfan Anemia

Russian Federation
Bayer

Completed

Radium-223 Dichloride Long-term Follow-up Program

Neoplasm Metastasis / Bone and Bones

Belgium, Spain, Taiwan, United States, Japan, Russian Federation, Canada, Finland, Korea, Republic of, Singapore, Australia, Germany, Israel, United Kingdom, Italy, France, Poland, Brazil, Czechia, Norway, Sweden, Hong Kong
Weill Medical College of Cornell University

Active, not recruiting

Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation

Hematologic Malignancy | Bone Marrow Transplant

United States
University Hospital, Brest

Recruiting

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms (AVAJAK)

Polycythemia Vera | Essential Thrombocythemia | High-risk Patients | Prefibrotic/Early Primary Myelofibrosis | JAK2 V617F

France

Clinical Trials on Bone Marrow Neoplasms

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations